Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. MGI Pharma was incorporated in 1979 under the name Molecular Genetics Inc and operated primarily as an animal health and agricultural biotechnology company. In the late 1980s, the company shifted its strategic focus to emphasise human pharmaceuticals and exited the animal health and agricultural business. In 1990, the company's name was changed to MGI Pharma Inc to reflect the change in focus to pharmaceuticals. Also in 1990, MGI purchased Didronel IV infusion from Procter & Gamble and began creating a commercial organisation.